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Abstract Overactive bladder affects millions of adults,
with profound personal and economic costs. Although
antimuscarinic drugs can cause a reduction in voiding
symptoms, the effect is modest, and many patients are
intolerant of the side effects, or do not experience suffi-
cient relief. For these patients, the modulation of bladder
reflex pathways via percutaneous tibial nerve stimulation
(PTNS) or via implanted sacral nerve stimulation (SNS)
has been acknowledged as a logical next step in the
algorithm of care. This review examines the mechanism
of action, the relative benefits, adverse effects, and costs
of percutaneous nerve stimulation compared to other
treatment modalities.
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Introduction
When behavioral therapy or pharmacology is not effec-
tive in the treatment of overactive bladder (OAB), the
modulation of bladder reflex pathways has been ac-
knowledged as the next logical step in the algorithm
of care. This care path has recently been codified in the
2012 American Urological Association guidelines for
the diagnosis and treatment of OAB [1••]. The two
most commonly utilized neuromodulation techniques
are percutaneous tibial nerve stimulation (PTNS) and
sacral nerve stimulation (SNS). Of note, although both
PTNS and SNS are believed to modulate neural path-
ways, PTNS and SNS are believed to target different
neural circuitry in the central nervous system. In addi-
tion, PTNS uses intermittent (weekly) stimulation of the
tibial nerve at the ankle with no permanent lead or
stimulator implanted, while SNS provides continuous
stimulation through surgical implantation of a permanent
electrode and a permanent pulse generator.
Based on three randomized trials and one long-term
durability trial [2–6, 7••], the National Institute for Health
and Clinical Excellence (NICE) in the United Kingdom,
issued guidance in October 2010 stating, “PTNS for OAB
demonstrates effectiveness without major safety concerns”
[8]. The United States Food and Drug Administration
(FDA) has cleared PTNS for treatment of overactive bladder
and the associated symptoms of urinary frequency, urinary
urgency and urinary urge incontinence, and a category I
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This review presents the currently available data regard-
ing the efficacy, long-term durability, adverse treatment
effects, and costs of percutaneous tibial nerve stimulation
in comparison with other OAB treatment modalities. This
review will discuss the place of PTNS in the current and
evolving OAB treatment algorithm, particularly for those
patients in whom pharmacological therapy does not meet
their expectations (lack of efficacy or poor tolerability).
Behavioral therapy is not included in this review as it is
acknowledged as a stand-alone treatment that can be used in
combination with other OAB therapies including pharma-
cotherapy or neuromodulation. Botulinum toxin is currently
not FDA approved for idiopathic OAB, and is not
included in this review. Similarly, although augmenta-
tion cystoplasty has been employed as a surgical alter-
native, the utilization of this relatively invasive intra-
abdominal procedure is limited.
Background
Overactive Bladder (OAB)
Approximately 34 million adults in the United States suffer
daily from Overactive Bladder (OAB) [9], defined by The
International Continence Society (ICS) as a syndrome with
or without urgency incontinence, usually associated with
urinary frequency and nocturia in the absence of proven
infection or other obvious pathology [10]. OAB affects
men and women equally, with women more likely to have
urinary urge incontinence than men (9.3 % vs. 2.6 %) and
with increasing incidence with age [9]. Urinary incontinence
can result in social isolation and depression, employment
disruption, as well as adversely impacting a patient’s quality
of life and sexual functioning [11]. Overall health care costs
in the USA attributed to OAB, including lost productivity,
have been estimated to be more than $65 billion per year
[12]. Urinary incontinence has also been linked to increased
morbidity, causing additional traumatic falls with associated
fractures [13]. Literature estimates for annual incidence of
OAB range from 2.6–143 cases per thousand, equivalent to
a 12 % prevalence rate, with the majority of patients suffer-
ing with symptoms for years [14]. Although there are a wide
variety of OAB treatment options, improvement in symp-
toms is ultimately the primary goal, as complete eradication
and resolution of chronic OAB symptoms is rarely achieved.
The sine qua non of urgency incontinence or OAB-wet is
overactive detrusor activity during bladder filling, although
symptoms of urgency may occur in the absence of detrusor
activity [11]. The first-line treatments for OAB are behav-
ioral therapies aimed at altering the patient’s habits and
response to the subjective sense of urgency [1••]. Although
these therapies are often effective, many patients do not
improve enough to meet their expectations. In these non-
responders, pharmacological therapy focuses on suppres-
sion of bladder symptoms by blocking cholinergic-
muscarinic receptors in the bladder with antimuscarinic
drugs. When behavioral therapy or pharmacologic strategies
are not effective, the modulation of bladder reflex pathways
with neuromodulation has been suggested as the next ther-
apeutic intervention. The utilization of intravesical botuli-
num toxin injection for refractory idiopathic OAB patients is
awaiting FDA approval and clinical integration and is not
discussed in this review.
Percutaneous Tibial Nerve Stimulation – The Clinical Data
Percutaneous tibial nerve stimulation therapy is provided in
the outpatient clinic setting. A 34-gauge needle electrode is
inserted approximately 5 cm cephalad to the medial malleolus
and posterior to the tibia (Fig. 1) with a surface electrode on
the arch of the foot; percutaneous nerve stimulation at a
current level of 0.5–9 mA at 20 Hz is performed initially for
30 minutes weekly for 12 weeks, followed by occasional
treatments as needed based on patient symptoms [4••, 5••, 6••].
The basic science supporting PTNS has been well de-
scribed in the published literature. In 1966, McPherson first
demonstrated in a cat model that stimulation of the cut ends
of dorsal spinal roots or various peripheral nerves including
the posterior tibial nerve, effectively inhibited bladder con-
tractions [15]. This effect was hypothesized to be mediated
by neural circuitry in the forebrain, as intercollicular decer-
ebration or thoracic spinal cord transection abolished the
effect [16]. In 1980, Sato and colleagues verified that elec-
trical stimulation of afferent nerves to hind limb muscles,
but not cutaneous afferents, inhibited reflex bladder activity
in the anesthetized cat [17]. In 1983, McGuire and Morris-
sey used electrical stimulation of the hindquarter nerves to
treat detrusor instability in spinal injured nonhuman pri-
mates [18], and then went on to demonstrate this effect in
16 humans [19]. These exploratory studies were followed
by multiple case series reports, and then by randomized,
controlled trials.
The posterior tibial nerve is a mixed sensory-motor
nerve, containing axons passing through the L4–S3 spinal
roots. The sacral roots also contain the peripheral nerves
involved in the sensory and motor control of the bladder and
pelvic floor, and are the same spinal tracts targeted by sacral
neuromodulation. Electrical stimulation of these nerves
inhibits bladder activity by stimulating large diameter so-
matic afferent fibers, which in turn evokes a central inhibi-
tion of the micturition reflex pathway in the spinal cord or
the brain. Although it is likely that stimulation of the sacral
roots, (SNS), stimulation of the pudendal nerve, and
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stimulation of the tibial nerve (PTNS) all affect central
components of the neural circuits controlling the bladder,
there may be significant differences. A recent study in a cat
model by Tai et al. demonstrated that both 5 and 30 Hz
stimulation of the posterior tibial nerve inhibits bladder
activity; however, stimulation of the pudendal nerve inhibits
bladder activity at 5 Hz but excites bladder activity at 20-
30 Hz [20]. In addition, repeated short duration stimulation
of the tibial nerve induces a persistent post-stimulation
inhibitory effect, and increases bladder capacity [20]. Unlike
the persistent inhibition seen with tibial nerve stimulation, it
appears that any change induced by SNS persists only while
the stimulator is turned on, returning to baseline in the
absence of chronic stimulation [21].
While the persistent inhibitory effects of tibial nerve
stimulation and the transient clinical effect of SNS are
dependent on somatic afferent modulation of spinal cord
reflexes and brain networks, the synaptic mechanisms are
unclear. The neural switching circuit for controlling bladder
capacity is located in the pontine micturition center (PMC),
and Tai et al. conclude that it is likely that the increased
bladder capacity results from direct modulation of the PMC
gating circuit or suppression of afferent input to that circuit
[20]. The stimulation locus (peripheral nerve vs. spinal
nerve root) and protocol (weekly and intermittent vs. chron-
ic and continuous) are quite different for PTNS and SNS,
and may utilize different spinal cord transmission routes
and thus induce central modulation in different ways.
Further study is required to understand the mechanisms
of action and determine the physiological reasons for
the differences seen in stimulation requirement and
durability of response.
Comparative Safety and Effectiveness of Current
Therapies for OAB
Most efficacy studies of OAB therapies present objective
measures, such as reduction in voids per day, nocturia, and
episodes of urge incontinence, as well as subjective meas-
ures of the patient’s perceived improvement in health status.
Although the ICS definition does not include urodynamic
criteria, some studies provide these data (volume of void,
maximum volume to trigger contraction) [7••, 22, 23]. Sub-
jective measures (reduction in perceived symptoms and
improvement in quality of life) are widely used, and may
represent the most valuable outcome measure [24, 25]. The
placebo or sham effect is particularly strong in OAB treat-
ment. A recent review of the placebo effect in such trials
reported that placebo pharmacologic treatment of urinary
tract symptoms yielded reductions in incontinence episodes
of 32-65 %, highlighting the need for an active comparative
arm in any OAB treatment study [24]. The SUmiT Trial
compared PTNS to a validated sham procedure and demon-
strated PTNS superiority to sham for both objective voiding
parameters and subjective patient assessments [5••]. In con-
trast, SNS studies do not include true placebo or sham arms,
thus treatment effect size cannot be assessed.
Fig. 1 Percutaneous tibial
nerve stimulation in the
outpatient setting. Reprinted
with permission from Peters et
al [5••]
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Outcome Measures––Objective Results
Percutaneous Tibial Nerve Stimulation
There are over 30 studies of PTNS in the published litera-
ture; the earliest are case series or single arm efficacy studies
[3, 7••, 23], three are randomized, controlled trials (RCT) [2,
5••, 6••], and two are long-term follow-up studies of patients
who were responders in the OrBIT and SUmiT Trials [4••,
26••]. Over half of the patients receiving PTNS therapy in
the SUmiT trial, a randomized, double-blinded, sham
controlled study, reported moderate or marked improve-
ment in bladder symptoms (54.5 % PTNS patients vs.
20.9 % sham, p<0.001) [5••]. In addition, PTNS re-
duced the number of voids per day from 12.3 at base-
line to 9.8 at 12 weeks, a mean reduction of -2.4 vs. a
reduction of -1.5 in the sham group (p<0.001). Urge inconti-
nence episodes per day decreased from 3/day at baseline to
0.3/day at 12 weeks vs. 1.8/day at baseline to 1.0/day for sham
(p<0.001) [5••]. In a randomized, controlled study, Finazzi-
Agro et al. report that PTNS significantly increased voided
volume compared to sham treatment (150 mL to 186 mL in
the PTNS treatment group vs. 146 mL to 150 mL in the sham
group, p <0.001) [2]. In a urodynamic study, Klingler et al.
report that PTNS increased mean total bladder capacity from
197 mL at baseline (range 35–349) to 252 ml (range 78–
384 mL, p<0.01) after 12 weeks of therapy [22]. When PTNS
was compared against tolterodine extended release in the
OrBIT study, both therapies demonstrated statistically signif-
icant improvements in incontinence episodes, voids per day,
and nocturia [6••]. Although the gains in voided volume
appear to be equivalently modest for both PTNS and for
antimuscarinics, these gains are associated with significant
improvements in subjective measures (see below), underscor-
ing that these changes are clinically meaningful. The demon-
strated increase in voided volume potentially represents an
additional hour of bladder capacity.
Antimuscarinic Therapy
The results for PTNS are comparable to those found in
Chapple’s recent systematic review and meta-analysis of
antimuscarinic drugs [27•]. A recent meta-analysis conclud-
ed that the significant improvement in OAB symptoms is
comparable between PTNS and antimuscarinics, but that
PTNS has a better adverse event profile [28]. Antimuscar-
inic drugs effect a reduction in incontinence episodes mod-
erately better than that seen with placebo, but with
bothersome adverse events for many patients. The relative
improvement in objective measures from baseline above
and beyond the placebo effect was modest but consistent
across drugs and doses. A recent AHRQ Comparative Ef-
fectiveness review concluded that the benefits seen with
antimuscarinics are small with no clear evidence for differ-
ential efficacy [29]. Urodynamic results are similar to those
obtained with PTNS, in that pharmacological treatments
typically increase voided volume by 13-39 mL [27•].
Sacral Neuromodulation
SNS studies typically only include patients who have expe-
rienced a positive result with test stimulation, and thus do
not include “non-responders” in intent-to-treat outcome
rates [21]. Virtually none of the studies include a true sham
group, as subjects can appreciate when the SNS electrode is
stimulated. A recent Cochran review of the randomized SNS
studies concluded that none were of adequate quality due to
lack of sham groups and/or blinding [21]. In a recent review
by Cameron of Medicare medical claims data, only 45.8 %
of the percutaneous test stimulation patients went on to
permanent implantation, and only 35.4 % of those with
two-stage test stimulation underwent subsequent implanta-
tion [30]. Despite these limitations, the reported results
indicate that 80–90 % of patients who received a permanent
implant experienced a greater than 50 % improvement in
their objective symptoms, with a significant decrease in
incontinent episodes per day [21, 31]. Kessler, in a meta-
analysis of the same studies reported that the pooled success
rate for the test period was 68 %, and 92 % for permanent
SNS [32].
Outcome Measures––Subjective Results (Quality of Life)
Although subjective measures of health-related quality of
life (HRQL) are often viewed as less reliable than objective
ones, Van Leeuwen and colleagues note that OAB symp-
toms primarily affect quality of life (QOL), and that “assess-
ing QOL and patient satisfaction should constitute an
integral part of treatment efficacy assessment [24].” Virtu-
ally all trials of therapy for overactive bladder include at
least one subjective measure of symptom reduction or
HRQL in addition to the objective measures. Direct com-
parison of HRQL measures between studies is limited by the
wide variety of instruments used; however all of these
measures are validated, as are those used in PTNS studies
[27•, 33, 34•]. A clear relationship between subjective and
objective outcome measures has been demonstrated, such
that therapies that show objective improvement in voids or
incontinence episodes per day also find significant improve-
ment in HRQL measures [5••, 6••, 34•]. Often the benefit
seen in the HRQL measure is more positive than that seen
with the objective measures. This may be related to a less-
ening of the distressing urge symptoms, thus patients are
more comfortable throughout the day, even though they may
void only 1–2 times less a day. A recent meta-analysis of the
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impact of antimuscarinic drugs on HRQL measures found
that antimuscarinics improve several areas of HRQL, that
these improvements are likely to be clinically meaningful,
and that there were not significant differences between anti-
muscarinic drugs in degree of impact [35].
Similarly, the three randomized studies of PTNS included
HRQL measures, and found that symptom severity score
was significantly reduced when compared to sham treatment
[5••], and mean quality of life was improved [2]. In the
OrBIT trial comparing PTNS to tolterodine ER (4 mg/
day), 79.5 % of women considered themselves cured or
improved with PTNS versus only 60.5 % of tolterodine
patients [6••]. In addition, subjective improvement was
greater with PTNS than tolterodine for overall HRQL, and
for each of four subscales (coping, concern, sleep and so-
cial) [6••].
The HRQL changes associated with SNS are inconsis-
tent. In their review of the SNS studies that report quality of
life changes with SNS, Herbison and Arnold note that it is
difficult to know how many separate studies of SNS exist, as
at least three appear to be sub-group analyses of the same
study [21]. In one report, the effect on general health status
as measured by the SF-36 was not significant, while in
another it was highly significant. Given these inconsisten-
cies between reports from the same study, Herbison and
Arnold conclude that the effect of SNS on quality of life is
still unclear [21].
Long-Term Durability
In a 12-month study of patients who were responders to
PTNS in the OrBit trial, on-going therapy with PTNS at
lengthening intermittent intervals (average interval of
24.7 days) resulted in a sustained therapeutic effect in daily
voids, urge incontinence episodes, and nocturia [4••]. A
similar study conducted in patients who were responders
in the SUmiT trial demonstrated sustained safety and effi-
cacy of PTNS through 24 months, with an average of 1.3
treatments per month [26••].
Few data exist regarding the long-term durability of any
pharmacological treatment of OAB; in the Chapple review
of antimuscarinic trial reports, only two trials had durations
greater than 12 weeks (16 and 52 weeks), providing few
data about long term durability of drug therapy [27•]. Al-
though the drug effect may be sustained, Gopal et al. report
that 77.2 % of patients discontinue use within the first year
with a mean of only 4.8 months of treatment [36•]. As with
drug therapy, SNS must be continued for the duration of the
patient’s life in order to be effective, and re-operation to
change the stimulator battery is required every 3–7 years.
Two long-term studies of SNS report a decrease of 31–45 %
in mean and median voids per day at six months and two
years, with a slight decrease in efficacy at five years (23 %
decrease in symptoms from baseline) [21].
Adverse Effects
Adverse events associated with PTNS are reported as mild,
transient and relatively uncommon at 1–2 %, including
bruising or bleeding at needle site, tingling and mild pain
[5••, 6••]. The long-term durability studies reported similar
mild and transient effects [4••, 26••]. Reports of adverse
effects of antimuscarinics range from 9.7–63 %, with the
most common adverse effects being constipation, dry
mouth, impaired urination, and urinary tract infection
[27•]. Serious adverse events were rare, but virtually all
studies show a significantly higher rate of any adverse event
with antimuscarinic therapy versus placebo [37]. The in-
creased rate of adverse events with drug therapy may ex-
plain the high discontinuance within the first year of use
[35].
Adverse events in SNS patients include pain at the im-
plant site (15.3 %), new pain (9 %), suspected lead migra-
tion (8.4 %), infection (6.1 %), transient sensation of electric
shock (5.5 %) and pain at lead site (5.4 %) [21], with 33–
67 % of patients requiring surgical revision of the implant or
leads within five years (includes battery changes) [37].
Relative Cost of Therapy
As presented in the American Urological Association
(AUA) Guidelines for treatment of OAB [1••], the syndrome
of OAB represents a continuum of symptoms, with various
therapies instituted along the treatment algorithm, and with
varying costs. Behavioral therapies are noninvasive and
inexpensive, but not free, as they require dedicated staff
for training and follow-up. This conservative therapy can
and should be offered to patients at any point in their care.
Treatment with generic tolterodine is approximately $1200
per year, while the newer, branded medications may cost
more than $200 per month [38]. The overall medical costs
for OAB patients receiving antimuscarinic therapy, includ-
ing office and ER visits, teaching, and laboratory costs, is
estimated to be approximately $2,000 more than behavioral
therapy alone [37].
A cost analysis of PTNS has not been published. Using
the recently published 2012 Medicare Physician Fee Sched-
ule with 3.80 total RVUs (relative value units) assigned to
CPT Code 64566 and the Medicare national average physi-
cian in-office reimbursement of $134 per treatment, the cost
of the first year of PTNS treatment would be approximately
$3,500. This includes the initial 12 treatments, followed by
an average of 12 treatments over the next 9 months and a
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total of five office visit charges throughout the therapy.
Subsequent costs taper off with the diminishing require-
ments of ongoing therapy. Patients who elect to discontinue
therapy can do so without additional surgical intervention or
costs. SNS therapy is more expensive when discontinued, as
corrective surgery to remove the electrodes and neurostimu-
lator is required.
A recent cost analysis of interventions for antimuscarinic
refractory patients reported SNS to be the most expensive, at a
base rate of $26,269 for 3 years therapy (initial implantation
plus revisions and management of adverse events) [39].
Augmentation cystoplasty, a more invasive surgical proce-
dure, was estimated to cost $14,337 over 3 years, with botu-
linum toxin injection (not currently an FDA cleared therapy
for idiopathic OAB) costing $7,651 over 3 years [39].
OAB Algorithm
Patients with overactive bladder present with an entire spec-
trum of symptoms, frommild to severe frequency and urgency
with or without mild to debilitating urge incontinence. As
outlined by the AUA Guidelines, the OAB algorithm of care
must include treatment options based upon individual presen-
tation and expectations of treatment outcomes [1••]. As shown
in Fig. 2, these treatment options move through increasingly
invasive and expensive levels (Fig. 3), from lifestyle and
behavioral changes through pharmacotherapy, office-based
neuromodulation with PTNS, surgical implantation (SNS)
and other surgical options. Although the AUAOAB algorithm
suggests both PTNS and SNS can be offered as equivalent
third tier options, our algorithm suggests that PTNS should be
considered as a treatment option prior to SNS, due to the fact
that PTNS is less invasive, has fewer adverse events, and a
lower cost than SNS.
Approximately 40 % of the 34 million adult patients with
OAB actively seek treatment. Lifestyle and behavioral inter-
ventions can influence voiding parameters at minimal expense
to the patient and healthcare system, and should be offered at
the beginning of care. Patients who continue to have troubling
symptoms should be offered antimuscarinic drugs, which
have demonstrated significant objective and subjective bene-
fit, albeit modest [27•]. Persistence with anticholinergic drugs
appears to be low, however, with poor adherence to medica-
tion for those who begin drug therapy; this patient population
would benefit from additional effective therapies.
As described earlier, there are two types of neuromodula-
tion that have been proven to be clinically effective. While
there are no head-to-head RCTs that compare PTNS and SNS,
it seems reasonable that patients should first be offered a
treatment regimen of PTNS, as it is office-based, less invasive,
and less expensive than SNS. The evidence reviewed above
demonstrates that PTNS can effectively reduce OAB symp-
toms in the majority of patients within weeks of beginning
therapy and that this benefit is sustained over time in respond-
ers. A recent study also showed that PTNS can be effectively
added to drug therapy, gaining additional benefit when com-
pared to drug alone, and that PTNSmay permit a lower dose of
drug for equivalent relief [40]. If peripheral neuromodulation
proves to be ineffective, patients can subsequently be treated
with the more invasive, permanent and costly SNS, with
augmentation cystoplasty as the final most invasive option.
Conclusions
The impact of OAB is profound in both personal and eco-
nomic terms. The existence of more than 30 FDA-clearedFig. 3 Relative costs of therapeutic options for overactive bladder
Fig. 2 OAB treatment algorithm, progressing from the least expensive and noninvasive therapy of lifestyle and behavioral changes, through drug
therapy, intermittent PTNS, surgically implanted SNS, and finally surgical interventions. (*Botulinum is not in the treatment algorithm as it is not
currently an FDA approved therapy for idiopathic OAB.)
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therapies highlights the need for evidence based treatment
options and an algorithm for the logical and efficient insti-
tution of therapy. Although antimuscarinic therapy is effec-
tive, pharmacological therapy will often not meet patient
expectations. While SNS has been shown to be efficacious,
the relative financial cost and the need for surgical implan-
tation and surgical revision should be considered. PTNS
provides an option for patients who are refractory to anti-
cholinergic therapy; it is less invasive and less costly than
SNS, and should be positioned early in the treatment algo-
rithm of care for OAB.
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